The Wall Street Journal: Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market
Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.
The talks have been going on for a while, but any agreement isn’t likely for another few weeks or more — and there may not be one.
Qiagen QGEN,
A deal between Qiagen and Bio-Rad would be the latest tie-up in the medical-diagnostic market, which has grown as the pandemic helped increase demand for testing.
An expanded version of this report appears at WSJ.com.
Trending at WSJ.com:
The two words that terrify junior employees
Paris cuts the lights to save energy. Will it help?
More biotech and health news:
Boston health officials worried about levels of COVID in wastewater
Israeli biotech Polyrizon to offer 3.1 million units in IPO priced at $5.20 to $7.20 each
This biotech company is lowering the cost of gene sequencing
Responses